Apinovo Pharma Innovations

What Apinovo Pharma Innovations does

Apinovo Pharma Innovations is a privately held, sub-10-person pharmaceutical process chemistry firm headquartered within the Institute for Life Science Entrepreneurship (ILSE) at 1000 Morris Ave, Union, New Jersey. The company develops novel synthetic routes for Active Pharmaceutical Ingredients (APIs), with explicit emphasis on replacing decades-old manufacturing processes, eliminating harmful impurities (including carcinogens such as N-Nitroso Dimethyl Amine), and implementing green chemistry principles. It targets generic pharmaceutical companies and supply-chain-exposed pharma buyers, prioritizing APIs selected by market value, manufacturing cost, and the company's ability to introduce innovation into the synthesis.

Apinovo's core service offering is the design of new synthetic routes developed in-house up to the N-2 intermediate stage, with claims of greater than 90% process innovation, followed by scale-up to 1-10 Kg batches to produce an integrated technology package. The company then partners with external manufacturers for cGMP scale-up and assists clients with revisions to Drug Master Files (DMFs), positioning its work for the FDA's stated favorable consideration of new DMFs incorporating innovative technologies. Its distinguishing capabilities are concentrated in its scientific bench: a Scientific Advisory Board featuring Nobel Laureate Robert H. Grubbs, Cambridge's Steven Ley, and Howard University's Joseph Fortunak, supported by an executive team including ex-BMS VP and Ranbaxy R&D President Rashmi Barbhaiya (CEO) and former Genzyme VP Mukund Chorghade (CSO).

The business model is services- and partnership-driven, with revenue expected to flow from technology licensing, development agreements, and collaboration arrangements rather than proprietary product sales. Pricing is not publicly disclosed; engagement is solicited via direct outreach and a website contact form. The company operates as a domestic US provider, aligning its value proposition with post-COVID supply chain reshoring and reducing dependency on APIs sourced from India and China. No funding rounds, customers, patents, or completed partnerships are disclosed in the available data.

Name

Apinovo Pharma Innovations

Legal name

Apinovo Pharma Innovations

Website

https://apinovo.com

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

Apinovo Pharma Innovations is a private, sub-10-person process chemistry firm in Union, New Jersey that develops novel synthetic routes and green chemistry methods for Active Pharmaceutical Ingredients, targeting generic pharmaceutical companies and US drug supply chain reshoring, and partnering with manufacturers for cGMP scale-up.

Ownership category

akta.pro rank

Product category

Pharmaceutical Process Chemistry Services

NAICS

Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Small-Molecule API Process Development & Route Scouting (HLAGAHAA)

akta.pro secondary industries

Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)

Keywords

• API process chemistry
• Novel synthetic routes
• Active pharmaceutical ingredients
• Green chemistry manufacturing
• Process optimization services

Headquarters

HQ city

Union

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. Technology Development and Licensing: Apinovo develops novel process chemistry technology and appears to generate revenue through technology licensing and strategic partnerships with manufacturers for cGMP scaleup. The company creates integrated technology packages and implements changes to DMFs (Drug Master Files).

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Apinovo Pharma Innovations develops novel process chemistry for the synthesis of active pharmaceutical ingredients (APIs), including the design of new synthetic routes, green chemistry approaches, impurity mitigation strategies, and N-2 intermediate processes. The company scales up these routes to the 1-10 Kg level in-house and then partners with cGMP manufacturers for commercial-scale production. Its services help generic and supply-chain-challenged pharma companies secure reliable, FDA-considerate manufacturing pathways for critical drug substances.

Product overview

Apinovo Pharma Innovations offers a suite of process chemistry services focused on API synthesis and manufacturing improvement. The company provides innovative route selection and API manufacturing process optimization as core offerings, complemented by strategic cGMP scale-up partnerships and DMF optimization services. Their approach centers on developing novel synthetic routes up to N-2 intermediate (>90% process innovation) before partnering with manufacturers for eventual cGMP scaleup. The company leverages green chemistry principles and advanced technologies to address supply chain vulnerabilities, eliminate harmful impurities, and reduce manufacturing costs.

Differentiator

Problem solved

Functional benefit

Products and services

• API Manufacturing Process Optimization
• Innovative Route Selection & Design
• cGMP Scale-up Partnership
• DMF Optimization Support

Quantifiable outcome

• Process innovation exceeding 90% up to N-2 intermediate stage

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Hovione: Specialty CDMO focused on small-molecule API process development, scale-up, and commercial manufacturing with a strong emphasis on innovative synthetic routes and particle engineering—directly comparable to Apinovo's route scouting and scale-up-to-partner model.
• Curia (formerly AMRI): Global CDMO offering small-molecule API process chemistry, scale-up, and cGMP manufacturing—directly comparable offering for the same generic-pharma customers and similar technical scope.
• Sterling Pharma Solutions: CDMO specializing in small-molecule API development and cGMP manufacturing, with significant investment in green and sustainable chemistry—directly competitive in process-chemistry and impurity-control positioning.
• PCI Synthesis: U.S.-based custom API development and manufacturing CDMO with strong process-chemistry capabilities targeting early-stage innovators and generic pharma—directly competing for the same client mandates.
• Cambrex (now part of Pharmaron Small Molecule): CDMO providing API development and manufacturing from process R&D through commercial scale—competing head-to-head for generic-pharma route-scouting and process-improvement mandates that Apinovo targets.
• Veranova (formerly Johnson Matthey Health): Specialty CDMO focused on API development, complex chemistry, and HPAPI manufacture with a licensing/process-chemistry offering to pharma—both competes with and could partner with Apinovo in the route-scout-to-scale space.

Emerging players

• Codexis: Engineered enzyme and process-chemistry platform company that licenses innovative biocatalytic and chemocatalytic routes into pharma API manufacturing—comparable technology/business model (IP + licensing) addressing the same route-innovation problem.
• Sai Life Sciences: CRO-CDMO offering process R&D, route scouting, and API manufacturing—analogous in scope and target customer base to Apinovo, with growing capacity in custom synthesis and process chemistry.
• PharmaCore (now part of Seqens): Small-molecule API CDMO with process development and cGMP capabilities focused on complex chemistry and small-batch manufacturing—comparable offering profile and customer segment.

Broad incumbents

• WuXi STA (PharmaTurn): Largest China-based API CRDMO with end-to-end process development through commercial manufacturing—operates as a broad incumbent in the same small-molecule API outsourcing category but at vastly greater scale and with integrated capacity.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

• Xtwitter.com/apinovo
• LinkedInlinkedin.com/company/apinovo-pharma-innovations

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Apinovo Pharma Innovations